DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Finn R.
Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase
(CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for
first-line treatment of ER+/HER2- advanced breast cancer (BC). Publication
Number S1-6 2012 San Antonio Breast Cancer Symposium (SABCS).
Texas: San Antonio; 2012
We do not assume any responsibility for the contents of the web pages of other providers.